Introduction
tumour
ONCOGENESIS, TUMOUR
Regorafenib is an oral multitargeted kinase inhibitor that blocks the activity of several protein kinases associated with angiogenesis, oncogenesis, and tumour microenvironmentThe standard starting dose of regorafenib is 160 mg/day regardless of patient height, body weight, race, and other parameters. However, continuous treatment at this dose tends to be complicated in routine medical care by its associated side effects, and therefore, the treatment dose often needs to be reduced to ≤ 120 mg/day. In the CORRECT trial, only 20% of participants required a reduction in regorafenib dose